Celgene Corporation - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 141 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Celgene Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Celgene Corporation - Product Pipeline Review - 2014', provides an overview of the Celgene Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celgene Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Celgene Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Celgene Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Celgene Corporation's pipeline products

Reasons to buy

- Evaluate Celgene Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Celgene Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Celgene Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Celgene Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celgene Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Celgene Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Celgene Corporation Snapshot 9
Celgene Corporation Overview 9
Key Information 9
Key Facts 9
Celgene Corporation - Research and Development Overview 10
Key Therapeutic Areas 10
Celgene Corporation - Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products - Monotherapy 18
Pipeline Products - Combination Treatment Modalities 19
Pipeline Products - Partnered Products 20
Partnered Products/Combination Treatment Modalities 21
Pipeline Products - Out-Licensed Products 23
Out-Licensed Products/Combination Treatment Modalities 24
Celgene Corporation - Pipeline Products Glance 25
Celgene Corporation - Late Stage Pipeline Products 25
Pre-Registration Products/Combination Treatment Modalities 25
Filing rejected/Withdrawn Products/Combination Treatment Modalities 26
Phase III Products/Combination Treatment Modalities 27
Celgene Corporation - Clinical Stage Pipeline Products 28
Phase II Products/Combination Treatment Modalities 28
Phase I Products/Combination Treatment Modalities 29
Celgene Corporation - Early Stage Pipeline Products 31
Preclinical Products/Combination Treatment Modalities 31
Discovery Products/Combination Treatment Modalities 32
Celgene Corporation - Drug Profiles 33
apremilast 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
lenalidomide 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
romidepsin 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
amrubicin hydrochloride 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
azacitidine 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
paclitaxel 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pomalidomide 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CC-223 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CC-11050 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CC-292 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
cenplacel-L 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GED-0301 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CC-115 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ARRY-382 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CC-122 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CC-220 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CC-90001 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
EPZ-5676 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GI-6301 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PDA-002 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
UCB + HPDSC 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ABI-013 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AVL-181 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AVL-192 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
CC-0730671 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CC-2142 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CC-509 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CC-539 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
CC-90002 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CC-90003 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
CNX-1351 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
CTP-730 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
IMiDxl 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules For Cancer and Inflammation 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CC-0739623 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
CC-2141 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
CSC-1 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Drug to Inhibit Kinase for Inflammation 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Drugs for Hematology and Oncology 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Early Targets 1-5 Program 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
EPIpros-1 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
EPIpros-2 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecules for Inflammation 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Celgene Corporation - Pipeline Analysis 93
Celgene Corporation - Pipeline Products by Target 93
Celgene Corporation - Pipeline Products by Route of Administration 96
Celgene Corporation - Pipeline Products by Molecule Type 97
Celgene Corporation - Pipeline Products by Mechanism of Action 98
Celgene Corporation - Recent Pipeline Updates 100
Celgene Corporation - Dormant Projects 127
Celgene Corporation - Discontinued Pipeline Products 131
Discontinued Pipeline Product Profiles 131
CC-1088 131
satraplatin 131
Celgene Corporation - Company Statement 132
Celgene Corporation - Locations And Subsidiaries 134
Head Office 134
Other Locations & Subsidiaries 134
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141

List of Tables
Celgene Corporation, Key Information 9
Celgene Corporation, Key Facts 9
Celgene Corporation - Pipeline by Indication, 2014 12
Celgene Corporation - Pipeline by Stage of Development, 2014 17
Celgene Corporation - Monotherapy Products in Pipeline, 2014 18
Celgene Corporation - Combination Treatment Modalities in Pipeline, 2014 19
Celgene Corporation - Partnered Products in Pipeline, 2014 20
Celgene Corporation - Partnered Products/ Combination Treatment Modalities, 2014 21
Celgene Corporation - Out-Licensed Products in Pipeline, 2014 23
Celgene Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 24
Celgene Corporation - Pre-Registration, 2014 25
Celgene Corporation - Filing rejected/Withdrawn, 2014 26
Celgene Corporation - Phase III, 2014 27
Celgene Corporation - Phase II, 2014 28
Celgene Corporation - Phase I, 2014 29
Celgene Corporation - Preclinical, 2014 31
Celgene Corporation - Discovery, 2014 32
Celgene Corporation - Pipeline by Target, 2014 94
Celgene Corporation - Pipeline by Route of Administration, 2014 96
Celgene Corporation - Pipeline by Molecule Type, 2014 97
Celgene Corporation - Pipeline Products by Mechanism of Action, 2014 98
Celgene Corporation - Recent Pipeline Updates, 2014 100
Celgene Corporation - Dormant Developmental Projects,2014 127
Celgene Corporation - Discontinued Pipeline Products, 2014 131
Celgene Corporation, Other Locations 134
Celgene Corporation, Subsidiaries 135